Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Gemigliptin and Metformin After Oral Administration in Healthy Mexican Male Subjects

Trial Profile

A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Gemigliptin and Metformin After Oral Administration in Healthy Mexican Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Gemigliptin (Primary)
  • Indications Acute kidney injury; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Sep 2018 Primary endpoint (Gemigliptin AUC,ss Geometric Mean Ratio (and 90%CI)) has not been met, according to results published in the Clinical Therapeutics.
    • 12 Sep 2018 Results published in the Clinical Therapeutics.
    • 21 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top